Sport Investors League
  • Politics
  • Stocks
  • Investing
  • Business

Sport Investors League

  • Politics
  • Stocks
  • Investing
  • Business
Investing

FDA Fast Track Designation for Narmafotinib in Advanced Pancreatic Cancer

by admin September 20, 2024
September 20, 2024
FDA Fast Track Designation for Narmafotinib in Advanced Pancreatic Cancer

Amplia Therapeutics Limited (ASX: ATX), (“Amplia” or the “Company”), is pleased to announce that the United States Food and Drug Administration (FDA) has granted Fast Track Designation to Amplia’s Focal Adhesion Kinase inhibitor, narmafotinib, for the treatment of advanced pancreatic cancer.

HIGHLIGHTS

The US FDA has granted Fast Track Designation to Amplia’s lead drug narmafotinib in advanced pancreatic cancerFast Track Designation facilitates the development of investigational drugs and allows for expedited review

Fast Track Designation is available to drugs that may provide an advantage over current therapies in the treatment of serious conditions. It is designed to speed the development of these drugs to enable patients to receive them sooner. This Designation will grant the Company access to more frequent meetings, and written communication, with the FDA. In future, narmafotinib may be eligible for Accelerated Approval and Priority Review. The Company has previously received Orphan Drug Designation from the FDA for narmafotinib in pancreatic cancer.

The Company’s CEO and Managing Director, Dr Chris Burns, commented, “Fast Track Designation for narmafotinib is a significant milestone for the Company. With this designation, we can work more closely with the FDA to accelerate our clinical program and gather the most compelling evidence for regulatory approval in this devastating disease.”

Amplia’s clinical trial in advanced pancreatic cancer, the ACCENT trial, is ongoing in Australia and South Korea. Earlier this year, the Company announced that the US FDA had cleared its IND1 application for a trial of narmafotinib in pancreatic cancer in the US. This trial is in advanced planning stages.

This ASX announcement was approved and authorised for release by the Board of Amplia Therapeutics.

Click here for the full ASX Release

This post appeared first on investingnews.com

0
FacebookTwitterGoogle +Pinterest
previous post
Boeing starts furloughing tens of thousands of employees amid machinist strike
next post
How to Invest in Silver (Updated 2024)

Related Posts

Will Rhind: Gold at All-time High, but Price...

April 12, 2025

Element 25 Share Purchase Plan Opens

May 27, 2024

Tudor to Acquire American Creek in Latest Gold...

June 27, 2025

Harvest Gold Identifies 15 Primary And 10 Secondary...

June 13, 2025

What are Junior Miners and Are They a...

September 20, 2024

Bitcoin Well Receives Receipt for Final Base Shelf...

March 8, 2025

Triumph Gold Updates Shareholders on Operations, Engages Market...

May 10, 2025

Cartier Resources Closes Offering with Paradigm Capital and...

April 24, 2025

High-Grade Gold Samples extend Clifton East Strike to...

May 22, 2025

CuFe Limited

July 18, 2025

    Get free access to all of the retirement secrets and income strategies from our experts! or Join The Exclusive Subscription Today And Get the Premium Articles Acess for Free


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Recent

    • JOSH HAMMER: Trial lawyer lawfare vs. Trump’s policy revolution

      September 21, 2025
    • Kamala Harris reveals what Biden told her just before crucial debate with Trump that left her ‘angry’

      September 21, 2025
    • MIKE DAVIS: Trump’s latest pick to reform the federal judiciary is another home run

      September 21, 2025
    • Trump caps UK trip with $350B tech pact, heads to Arizona for Kirk’s memorial service

      September 21, 2025
    • How AI browsers open the door to new scams

      September 21, 2025

    Categories

    • Business (1,107)
    • Investing (3,081)
    • Politics (3,763)
    • Stocks (1,155)
    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: sportinvestorsleague.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 sportinvestorsleague.com | All Rights Reserved